Moderna $MRNA (+7,21 %) cuts 2025 revenue forecast to $1.5B–$2.5B (from $2.5B–$3.5B) due to slower demand for COVID and RSV vaccines. 2024 sales hit $3.0B–$3.1B.
Cash costs to drop by $1B in 2025, with another $500M cut planned for 2026. CEO Bancel highlights focus on driving growth, 10 product approvals in 3 years, and further cost reductions. Full Q4 results coming Feb 14, 2025.
__
Abercrombie & Fitch $ANF (+2,46 %) raises its Q4 net sales forecast to +7%–8%, up from +5%–7%, citing strong holiday demand. Operating margin is expected around 16%. FY24 net sales now forecasted at +15% with a 15% operating margin. Record sales driven by strong comps across regions and brands. Full details at 2025 ICR Conference.
__
$LULU (+2,53 %) $LULu RAISES GUIDANCE: Lululemon updates Q4 2024 outlook with revenue now expected at $3.56-3.58B (prior $3.48-3.51B) and EPS at $5.81-5.85 (prior $5.56-5.64). Gross margin forecast improved by 30 bps. Strong holiday demand cited.